Hemophilia B Drug Report Published in New England Journal of Medicine
December 5, 2013; Posted by: webleed staff
The New England Journal of Medicine will publish data on December 12th demonstrating prophylactic infusions of Biogen Idec’s ALPROLIX effectively controlled bleeding in hemophilia B patients.
New data will be available on a factor replacement drug for those suffering from hemophilia B. The New England Journal College of Medicine will document the Phase 3 study of pharmaceutical company Biogen Idec’s new long lasting factor IX (9) drug in their online edition due out next week, December 12. The drug named APROLIX is the first long lasting hemophilia related drug of its kind.
The Phase 3 study of ALPROLIX, named B-LONG, showed that people with severe hemophilia B safely and effectively prevented or reduced bleeding episodes with prophylactic infusions every one to two weeks.
This development is shaping out to be a major advancement in hemophilia. To read more about the findings of the study and more analysis, click here.
Photo Credit – New England Journal of Medicine
UPDATED ARTICLE: December 8, 2013 – MedPageToday “Low Rate of Bleeding with Factor IX Fusion Protein”
